Despite growing therapeutic interest, clinical translation of CD24 targeting has been limited by tumor heterogeneity, redundancy among innate immune checkpoints, safety concerns related to physiological CD24 expression, and the absence of functional biomarker frameworks. Here, CD24 is linked to neoplasm.